☆ 4.8 Article

Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice

SCIENCE TRANSLATIONAL MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Letter Medicine, General & Internal

A step backwards in the fight against global vaccine inequities

Ernest Aryeetey et al.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett et al.

Summary: The study demonstrates that a booster dose of ChAdOx1 nCoV-19 is safer and better tolerated than priming doses. The booster dose significantly enhances anti-spike neutralizing antibody titers and other functional antibody responses. These data support the two-dose vaccine regime currently being evaluated in phase 3 clinical trials.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Summary: In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Microbiology

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19

Steven S. Good et al.

Summary: AT-527, an oral antiviral drug, has potent activity against various coronaviruses, including SARS-CoV-2. In vitro experiments have shown that AT-511 has high efficacy in inhibiting the replication of SARS-CoV-2, with minimal cytotoxicity. Studies suggest that AT-527 may be an effective treatment option for COVID-19.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Angela Wahl et al.

Summary: The study suggests that bats may be the source of coronaviruses that can be directly transmitted to humans. Using the LoM model, efficient replication of SARS-CoV, MERS-CoV, SARS-CoV-2, and two SARS-like bat coronaviruses in human lung tissue was demonstrated. Infection with SARS-CoV-2 predominantly targets human lung epithelial cells and induces a sustained inflammatory response. The broad-spectrum antiviral agent EIDD-2801 significantly inhibits SARS-CoV-2 replication in vivo, showing potential for prevention and treatment of COVID-19.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Rita E. Chen et al.

Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.

NATURE MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Escaping Catch-22-Overcoming Covid Vaccine Hesitancy

Lisa Rosenbaum

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets

Robert M. Cox et al.

Summary: Remdesivir is an antiviral drug approved for COVID-19 treatment, but its intravenous administration limits wider use. A study has shown that GS-621763, an oral prodrug of remdesivir parent nucleoside GS-441524, has good oral bioavailability and inhibits SARS-CoV-2 and variants of concern in ferrets, demonstrating therapeutic efficacy in a relevant animal model of SARS-CoV-2 infection.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir

Ross Martin et al.

Summary: The study reveals low genetic variation in the RNA replication complex of SARS-CoV-2, especially the RNA-dependent RNA polymerase (nsp12), which is the main target of remdesivir. The risk of pre-existing resistance to remdesivir is minimal.

ANTIVIRAL RESEARCH (2021)

添加到收藏夹

Article Chemistry, Medicinal

Prodrugs of a 1′-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV

Richard L. Mackman et al.

Summary: A discovery program identified C-nucleoside 4 as a potential lead compound for respiratory syncytial virus (RSV), which led to the discovery of the more potent drug remdesivir. In vitro metabolism studies confirmed the rapid formation of the active metabolite 1-NTP, and in vivo studies in monkeys showed significant reduction in lung viral load following administration of remdesivir. These early data supported the potential of remdesivir as a novel treatment for RSV prior to its development for other diseases.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Time for the ethical management of COVID-19 vaccines

Agnes Binagwaho et al.

Lancet Global Health (2021)

添加到收藏夹

Editorial Material Microbiology

SnapShot: SARS-CoV-2 antibodies

David C. Montefiori et al.

CELL HOST & MICROBE (2021)

添加到收藏夹

Editorial Material Microbiology

Global COVID-19 vaccine inequity: The scope, the impact, and the challenges

Archana Asundi et al.

Summary: Global vaccine inequity is prolonging the COVID-19 pandemic. Challenges in vaccine development, manufacturing, and distribution need to be addressed to resolve this crisis.

CELL HOST & MICROBE (2021)

添加到收藏夹

Editorial Material Infectious Diseases

Vaccine hesitancy in the COVID-19 era

Bipin Adhikari et al.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Microbiology

SARS-CoV-2 variants, spike mutations and immune escape

William T. Harvey et al.

Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.

NATURE REVIEWS MICROBIOLOGY (2021)

添加到收藏夹

Article Cell Biology

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

David R. Martinez et al.

Summary: Research shows that a combination of two mAbs in clinical trials has strong antiviral effects and therapeutic efficacy against certain variants, while combining RDV and antibodies slightly improves treatment outcomes, supporting the continued use of RDV to treat SARS-CoV-2 infections.

CELL REPORTS (2021)

添加到收藏夹

Article Microbiology

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2

Agnieszka M. Szemiel et al.

Summary: This study selected drug-resistant SARS-CoV-2 populations with decreased sensitivity to remdesivir (RDV) in vitro, identifying a mutation in NSP12 that decreases RDV sensitivity. There is no evidence of widespread transmission of RDV-resistant mutants among globally circulating SARS-CoV-2 variants. Additionally, emerging SARS-CoV-2 variants showed substitutions at Spike sites corresponding to those identified in vitro, indicating their potential to arise without immune selection.

PLOS PATHOGENS (2021)

添加到收藏夹

Letter Medicine, General & Internal

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Tomer Merison et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Timothy P. Sheahan et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Yixuan J. Hou et al.

CELL (2020)

添加到收藏夹

Article Cell Biology

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Timothy P. Sheahan et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study

Shufa Zheng et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Fei Zhou et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Compassionate Use of Remdesivir for Patients with Severe Covid-19

J. Grein et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Letter Infectious Diseases

Viral dynamics in mild and severe cases of COVID-19

Yang Liu et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

Sarah R. Leist et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Brandi N. Williamson et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Seth J. Zost et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Cell Biology

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

Andrea J. Pruijssers et al.

CELL REPORTS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Xuping Xie et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Immunology

US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2

Xiaoyan Lu et al.

EMERGING INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Ariane J. Brown et al.

ANTIVIRAL RESEARCH (2019)

添加到收藏夹

Article Microbiology

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Maria L. Agostini et al.

MBIO (2018)

添加到收藏夹

Article Cell Biology

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Timothy P. Sheahan et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

添加到收藏夹

Review Microbiology

A decade after SARS: strategies for controlling emerging coronaviruses

Rachel L. Graham et al.

NATURE REVIEWS MICROBIOLOGY (2013)

添加到收藏夹

Article Virology

Host Regulatory Network Response to Infection with Highly Pathogenic H5N1 Avian Influenza Virus

Chengjun Li et al.

JOURNAL OF VIROLOGY (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.